On October 26, 2020 Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, reported upcoming presentations at conferences and medical meetings (Press release, Arch Oncology, OCT 26, 2020, View Source;utm_medium=rss&utm_campaign=arch-oncology-to-present-at-upcoming-conferences [SID1234569041]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference:

Event: Stifel 2020 Annual Healthcare Conference
Date: November 17, 2020, 4:40 pm ET

Medical and Scientific Meetings:

Event: Macrophage-directed Therapies Summit 2020
Date: October 27-29, 2020

Event: CD47/SIRPα Summit 2020
Date: November 4-5, 2020

Event: SITC (Free SITC Whitepaper) Annual Meeting 2020
Date: November 11-14, 2020
Abstract Title: AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to b1 integrin

Event: PEGS Europe Virtual 2020
Date: November 9-13, 2020